Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease (vol 13, pg 1153, 2018)

被引：0
|
作者：
Bungum, Lisa A.
Chebib, Fouad T.
Czerwiec, Frank S.
Edwards, Marie E.
El-Zoghby, Ziad M.
Harris, Peter C.
Hogan, Marie C.
Irazabal, Maria V.
Kline, Timothy L.
Metzger, Andrew J.
Ofstie, Troy G.
Senum, Sarah R.
Torres, Vicente E.
机构：
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2019年 / 14卷 / 06期
关键词：
D O I：
10.2215/CJN.02810319
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：910 / 910
页数：1
相关论文
共 50 条
  • [1] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [2] Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease
    Cantarelli, Lorenzo
    Valencia, Marta Gutierrez
    Alegria, Leire Leache
    Fernandez, Luis Carlos Sainz
    Lopez, Juan Erviti
    Nicolas, Fernando Gutierrez
    Casariego, Gloria Julia Nazco
    MEDICINA CLINICA, 2024, 163 (01): : 1 - 7
  • [3] LONG-TERM SAFETY OF TREATMENT WITH TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Martins Munoz, Judith
    Espinel, Laura
    De Lorenzo, Alberto
    Tarragon, Blanca
    Teresa Naya, Maria
    Cubas, Alfonso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I15 - I15
  • [4] Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Shimoda, Naoko
    Ikeda, Mariko
    Yan, Tomohiro
    Kawasaki, Sayuri
    Hirama, Akio
    Kashiwagi, Tetsuya
    Sakai, Yukinao
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2022, 89 (03) : 287 - 294
  • [5] BENEFIT OF LONG-TERM TOLVAPTAN ADMINISTRATION ON KIDNEY DISEASE PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A SINGLE-CENTRE EXPERIENCE
    Filiopoulos, Vassilis
    Melexopoulou, Christina
    Kofotolios, Ioannis
    Stroppou, Persia
    Vallianou, Kalliopi
    Athanasopoulou, Diamanto
    Karavasilis, Efstratios
    Ntounas, Georgios
    Efstathopoulos, Efstathios
    Boletis, Ioannis
    Marinaki, Smaragdi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I238 - I239
  • [6] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Jouret, Francois
    Krzesinski, Jean-Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1258 - 1259
  • [7] Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
    Ingelfinger, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1988 - 1989
  • [8] Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
    Nakatani, Shinya
    Ishimura, Eiji
    Machiba, Yuri
    Fujimoto, Kenta
    Uedono, Hideki
    Tsuda, Akihiro
    Mori, Katsuhito
    Emoto, Masanori
    Inaba, Masaaki
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2020, 10 (01): : 9 - 17
  • [9] Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease
    Demiray, Alparslan
    Ozan, Ramazan
    Ozayturk, Salih Guntug
    Imamoglu, Hakan
    Zararsiz, Gokmen
    Sipahioglu, Murat Hayri
    Tokgoz, Bulent
    Elcik, Deniz
    Kocyigit, Ismail
    CARDIORENAL MEDICINE, 2024, 14 (01) : 167 - 177
  • [10] LONG-TERM FOLLOW-UP OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TREATED WITH TOLVAPTAN
    Martins Munoz, Judith
    De Lorenzo, Alberto
    Espinel, Laura
    Tarragon, Blanca
    Teresa Naya, Maria
    Cubas, Alfonso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I12 - I13
12345